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ABSTRACT
Background: Discrimination between benign and malignant tumors is a 
challenging process in pediatric adrenocortical tumors. New insights in the metabolic 
profile of pediatric adrenocortical tumors may contribute to this distinction, predict 
prognosis, as well as identify new molecular targets for therapy. The aim of this work 
is to characterize the expression of the metabolism-related proteins MCT1, MCT2, 
MCT4, CD147, CD44, GLUT1 and CAIX in a series of pediatric adrenocortical tumors.
Methods: A total of 50 pediatric patients presenting adrenocortical tumors, including 
41 clinically benign and 9 clinically malignant tumors, were included. Protein expression 
was evaluated using immunohistochemistry in samples arranged in tissue microarrays.
Results: The immunohistochemical analysis showed a significant increase in 
plasma membrane expression of GLUT1 in malignant lesions, when compared to benign 
lesions (p=0.004), being the expression of this protein associated with shorter overall 
and disease-free survival (p=0.004 and p=0.001, respectively). Although significant 
differences were not observed for proteins other than GLUT1, MCT1, MCT4 and CD147 
were highly expressed in pediatric adrenocortical neoplasias (around 90%).
Conclusion: GLUT1 expression was differentially expressed in pediatric 
adrenocortical tumors, with higher expression in clinically malignant tumors, and 
associated with shorter survival, suggesting a metabolic remodeling towards a 
hyperglycolytic phenotype in this malignancy.
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INTRODUCTION
Adrenocortical tumors (ACTs) are common neoplasms 
with a prevalence higher than 3% in individuals older than 
50 years, being the great majority of these tumors benign 
[1]. In opposition, adrenocortical carcinoma is a very rare 
and aggressive event, with an estimated annual worldwide 
incidence of 0.7-2 new cases per million [2-4]. In children, 
ACTs are an even more rare event, with an estimated annual 
worldwide incidence of 0.2-0.3 cases per million children 
younger than 15 years. Different groups have shown 
pediatric ACTs are different from adult ACTs [5-7], and, 
importantly, Weiss’ score [8], greatly useful in adults, cannot 
be applied to children to predict clinical behavior [6, 9, 10]. 
In fact, children with ACTs apparently with poor prognosis 
based on adult criteria often have a good clinical outcome 
[6, 11]. As a result, in 2003, Wieneke and collaborators, 
studying a series of 88 pediatric patients (<20 years) with 
ACTs, proposed a new score for children, based on invasion 
on vena cava, gross and microscopic features [11]. Although 
one study validates the reliability of Wieneke’s scoring 
system in predicting malignancy in pediatric ACTs [12], the 
series was small (only 13 patients) and this system did not 
gain a great acceptance in the literature yet. Interestingly, 
Southern Brazil shows an unusually high incidence of 
pediatric ACTs, with values of 3.4-4.2 per million [2, 4, 
13], a fact attributed to the high prevalence of the germline 
mutation p.R337H in TP53 [14-16]. Currently, complete 
resection is the best treatment option to achieve cure in 
this type of cancer [17, 18]; however, long-term survival 
in children is still limited, with 5-year survival rates greatly 
varying (virtually from 0% to 100%) as a consequence of 
different disease presentations [11, 17, 19-21]. Prognostic 
factors include age, mitotic rate, tumor weight, tumor size, 
tumor extension, margin status, and presence of metastasis 
[19, 22, 23].
The metabolic reprogramming of cancer cells 
towards aerobic glycolysis, one of the recently defined 
hallmarks of cancer [24], has gained renewed attention 
as a potential prognostic and therapeutic tool. As normal 
epithelial cells become hyperproliferative, they reach the 
oxygen diffusion limit, leading to a state of intermittent 
hypoxia. These hypoxic cells can either suffer cell death 
or suffer a metabolic adaptation to a glycolytic phenotype. 
In this metabolic reprogramming, also known as the 
Warburg effect, cancer cells, either in the presence or 
absence of oxygen, produce energy mainly through 
glycolysis, whereas pyruvate, instead of being used 
for oxidative phosphorylation in the mitochondria, is 
converted to lactate, in a much less energetically efficient 
process. As a result, cancer cells consume high amounts 
of glucose to obtain the necessary ATP for proliferation, 
and produce high amounts of lactate, which is expelled 
from the cell through specific transporters, contributing to 
extracellular acidification. To sustain the high glycolytic 
rates, many metabolism-related proteins are upregulated 
in cancer, mainly due to the activity of hypoxia inducible 
factor 1 alpha (HIF-1α), the transcription factor involved 
in cellular responses to hypoxia [25, 26]. In this context, 
monocarboxylate transporters (MCTs), responsible for 
lactate transport, their chaperones CD147 and CD44, 
as well as the glucose transporter 1 (GLUT1) and the 
pH regulator carbonic anhydrase 9 (CAIX) arise as key 
players in the metabolic reprogramming of cancer cells 
[27-29].
In a previous study by our group, this metabolic 
reprogramming was described in adult adrenocortical 
carcinoma, which was associated with cancer cell 
aggressiveness [30]. Considering discrimination between 
benign and malignant tumors is more challenging in 
pediatric ACTs than in adult tumors [5], new insights in 
the metabolic profile of pediatric tumors may contribute 
to this distinction, to predict prognosis as well as to 
identify new molecular targets for directed therapy. As 
a result, the aim of the present work is to characterize 
the expression profile of the metabolism-related proteins 
MCT1, MCT2, MCT4, CD147, CD44, GLUT1 and 
CAIX in a series of pediatric ACTs, and its relation with 
clinical behavior.
RESULTS
As shown in Figures 1, 2 and 3, the immuno-
histochemical expression of the metabolism-related 
proteins in childhood ACTs was found in the cytoplasm, 
the plasma membrane or both localizations, with a 
predominance of plasma membrane expression (except 
for CAIX). All 3 MCT isoforms, as well as the chaperone 
CD147, were expressed at high frequency in the plasma 
membrane of most tumor samples (around 60-90%) 
and, for MCT4, the frequency of expression was higher 
in malignant than in benign tumors, however, with no 
statistical significance. Overall, CD44 was less frequently 
expressed in tumor samples, being absent from malignant 
tumors. Regarding the other metabolism-related proteins, 
GLUT1 and CAIX, a significant increase in the plasma 
membrane expression of GLUT1 was observed in 
malignant tumors, compared to benign tumors (p=0.004), 
but no differences in CAIX expression were observed. 
Evaluation of co-expression of MCTs with the other 
proteins at the plasma membrane (Table 1) showed a 
significant association between MCT4 and both GLUT1 
and CAIX (p=0.002 and p=0.036, respectively).
Taking into account the results obtained for GLUT1, 
the value of GLUT1 expression as a diagnostic marker 
was investigated. The positive predictive value of GLUT1 
to characterize an adrenal mass as malignant was 41.2% 
while the corresponding negative predictive value to 
rule out malignancy was 93.9%, with a sensitivity of 
77.8%, a specificity of 75.6% and an accuracy of 76.0%. 
Also, survival analysis showed a significant association 
of GLUT1 plasma membrane expression with shorter 
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overall and disease-free survival (p=0.004 and p=0.001, 
respectively, Figure 4).
DISCUSSION
In a previous study evaluating the expression and 
clinical significance of metabolism-related proteins in 
adult ACTs, MCT4, GLUT1 and CAIX plasma membrane 
expressions were shown to be significantly increased in 
carcinomas, when compared to adenomas. Moreover, 
MCT1, GLUT1 and CAIX plasma membrane expressions in 
carcinomas were significantly associated with poor prognosis, 
while MCT2 at the plasma membrane was associated 
with good prognosis [30]. In fact, although the majority 
of studies in ACTs using 18F-fluorodeoxyglucose positron 
emission tomography (18F-FDG-PET) rely on data obtained 
mainly or entirely from adult samples, evidence suggest a 
possible clinical relevance of the glycolytic metabolism, as 
18F-FDG-PET may have both a diagnostic and prognostic 
value in adrenocortical malignancies [31-36]. Specifically 
in pediatric tumors, one study showed this technique was a 
satisfactory tool for metastasis screening [37] while another 
showed avid uptake of 18F-FDG by pediatric adrenocortical 
carcinoma [38]; however, both studies were based only on 
results from one patient with this type of cancer. Additionally, 
comparative studies in adult ACTs showed carcinomas, 
in opposition to adenomas, present biochemical markers 
Figure 1: Immunohistochemical expression of MCT1 (A), MCT2 (B), MCT4 (C), CD147 (D), CD44 (E), GLUT1 (F) and 
CAIX (G) in a benign childhood adrenocortical tumor. Magnification: 400x.
Figure 2: Immunohistochemical expression of MCT1 (A), MCT2 (B), MCT4 (C), CD147 (D), CD44 (E), GLUT1 (F) and 
CAIX (G) in a malignant childhood adrenocortical tumor. Magnification: 400x.
Oncotarget63838www.impactjournals.com/oncotarget
indicative of increased glycolysis (such as lactate) [39], as 
well as increased levels of GLUT1 [40] and aldolase A, also 
a glycolytic enzyme, and decreased levels of proteins related 
to mitochondrial activity [41], also suggesting a metabolic 
reprogramming compatible with the Warburg effect. 
However, no similar studies are available for pediatric ACTs.
Following this line of evidence, in the present study, 
we characterized the expression of the glycolytic-related 
proteins: MCT1, MCT2, MCT4, CD147, CD44, GLUT1 
and CAIX, in a series of pediatric ACTs. To the best of our 
knowledge, this is the first study aiming to characterize the 
metabolic profile of pediatric ACTs.
Herein, in line with the metabolic shift from an oxidative 
to a glycolytic phenotype, GLUT1 plasma membrane expression 
was significantly increased in malignant tissues, compared to 
benign tissues, similarly to results from adult adrenocortical 
Figure 3: Frequency of expression of the different proteins analyzed in benign and malignant adrenocortical tumors. 
Pearson’s chi-square (χ2) test or Fisher’s exact test was used to assess differences of expression frequency between benign and malignant 
tumors. Cyt - cytoplasmic expression; PM - plasma membrane expression; * p=0.004.
Table 1: Co-expression of MCTs with CD147, CD44, GLUT1 and CAIX, in childhood adrenocortical tumor samples 
(benign and malignant). Only plasma membrane expressions were considered
n MCT1 MCT2 MCT4
Positive (%) p Positive (%) p Positive (%) p
CD147 1.000 0.197 0.118
 Negative 8 7 (87.5) 4 (50.0) 3 (37.5)
 Positive 42 35 (83.3) 32 (76.2) 29 (69.0)
CD44 1.000 0.278 1.000
 Negative 38 32 (84.2) 29 (76.3) 24 (63.2)
 Positive 12 10 (83.3) 7 (58.3) 8 (66.7)
GLUT1 1.000 0.511 0.002
 Negative 33 28 (84.8) 25 (75.8) 16 (48.5)
 Positive 17 14 (82.4) 11 (64.7) 16 (94.1)
CAIX 0.173 0.140 0.036
 Negative 38 30 (78.9) 25 (65.8) 21 (55.3)
 Positive 12 12 (100.0) 11 (91.7) 11 (91.7)
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Table 2: Clinicopathological data of the pediatric adrenocortical tumor patients
Variable n %
Age# (n=50)
  ≥ 2.2 years 28 56.0
  < 2.2 years 22 44.0
Gender (n=50)
  Female 30 60.0
  Male 20 40.0
  TP53 germline mutation status (n=34)
  Wild type 8 23.5
  Mutated 26 76.5
Tumor size (n=50)
  < 5 cm 20 40.0
  ≥ 5 cm 30 60.0
Tumor weight# (n=48)
  < 40.0 mg 21 43.8
  ≥ 40.0 mg 27 56.3
Weiss score (n=49)
  1 4 8.2
  2 5 10.2
  3 5 10.2
  4 7 14.3
  5 11 22.4
  6 9 18.4
  7 6 12.2
  8 1 2.0
  9 1 2.0
Nuclear grade* (n=18)
  Low 4 22.2
  High 14 77.8
Mitotic index* (n=18)
  Low 9 50.0
  High 9 50.0
Atypical mitosis (n=18)
  Absent 8 44.4
  Present 10 55.6
Necrosis (n=18)
  Absent 11 61.1
  Present 7 38.9
(Continued )
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carcinomas [30, 40]. Also, GLUT1 expression was associated 
with shorter overall and disease-free survival, indicating this 
protein can contribute to predict malignancy in pediatric ACTs, 
as, presently, there is no adequate scoring system to predict 
clinical behavior in this type of tumor [6, 9-11]. In opposition, 
although expressed at high frequencies at the plasma membrane 
of neoplastic cells, the 3 MCT isoforms as well as the chaperone 
CD147 were not significantly differently expressed in benign 
Variable n %
Venous invasion (n=18)
  Absent 14 77.8
  Present 4 22.2
Sinus invasion (n=18)
  Absent 16 88.0
  Present 2 11.1
Capsular invasion (n=18)
  Absent 15 83.3
  Present 3 16.7
Metastasis (n=50)
  Absent 41 82.0
  Present 9 18.0
Staging (n=50)
  I 26 52.0
  II 20 40.0
  III 2 4.0
  IV 2 4.0
# Median values were used for cut-off as these variables followed a non-normal distribution. * Nuclear grade and 
mitotic index were defined according to Weiss score definitions [8].
Figure 4: Overall and disease-free survival curves of pediatric adrenocortical carcinomas’ patients. The results are 
stratified according to protein immunohistochemical expression. Only significant results are shown. Continuous line refers to positive 
expression while interrupted line refers to negative expression. (A) Association of GLUT1 plasma membrane expression with overall 
survival; (B) Association of GLUT1 plasma membrane expression with disease-free survival.
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and malignant samples. In fact, with the exception of MCT4, 
expression frequencies of these proteins were very similar 
between groups. To note, the malignant tumor group included 
only 9 samples, which may explain the lack of significance 
in MCT4 plasma membrane expression frequencies between 
groups, as the statistical power was only sufficient to detect high 
differences in expression frequencies, such as the one found for 
GLUT1. The lack of CD44 in malignant samples suggests this 
protein is not a chaperone for MCT1 or MCT4 in malignant 
ACTs and has no role in pediatric adrenocortical malignancy. 
Finally, CAIX, a pH regulator upregulated in a variety of cancers, 
including adult adrenocortical carcinomas [30], showed similar 
expression between benign and malignant samples, suggesting 
other pH regulator, such as CAXII, should be involved in the 
acid-resistant phenotype associated with the hyperglycolytic 
phenotype depicted by GLUT1 overexpression. Interestingly, 
although MCT4 and CAIX were not differently expressed in 
malignant samples, compared to benign samples, MCT4 was 
associated with GLUT1 and CAIX, which is coherent with 
a protein profile remodeling towards a hyperglycolytic and 
acid-resistant phenotype.
Considering pediatric ACTs and adult ACTs show 
different genetic backgrounds, such as TP53 mutations, as well 
as different molecular mechanism involved in tumorigenesis 
[5, 7], and oncogenes and tumor suppressors are important 
regulators of cancer cell metabolism [42], it is not surprising 
the expression of metabolism-related proteins in pediatric 
ACTs found in the present study shows some differences, 
when compared with a previous study with adult ACTs [30]. 
However, overall, the findings point at the same direction, 
which is a metabolic reprogramming towards a glycolytic 
phenotype in adrenocortical malignant tumors. Previous 
studies focusing on the biological aspects behind malignancy 
in pediatric ACTs have identified the insulin-like growth 
factor (IGF) system, specifically the pair IGF2/IGF1 receptor 
(IGF1R), as one of the molecular mechanisms involved in 
the process of tumorigenesis [43-46]. Although some of the 
signaling proteins downstream of IGF1R, such as Akt, mTOR 
and AMP-activated protein kinase (AMPK), have a pivotal 
role in cancer cell metabolic reprogramming [42, 47, 48], the 
possible role of IGF1R as a mediator of the Warburg effect has 
not been clearly established. Nevertheless, the use of a specific 
antibody targeting IGF1R in neuroblastoma and breast cancer 
xenograft models showed an antitumor activity, associated 
with a decrease in glucose uptake [49]. Additionally, IGF1R 
knockdown inhibited anchorage-independent growth of 
glioma cells, associated with a decreased glycolytic phenotype 
[50]. As a result, IGFR1 overexpression in pediatric malignant 
ACTs may be involved in a metabolic reprogramming towards 
a hyperglycolytic phenotype.
Targeting the metabolic reprogramming of cancer cells 
has been pointed out as a potential therapeutic tool and GLUT1 
emerges as one of the promising target protein [27, 51, 52]. 
In fact, promising results on GLUT1 targeting, alone or in 
combination with conventional treatment, in a variety of tumor 
models are being described [53-55] and, based on the results 
from the present study, we anticipate pediatric adrenocortical 
carcinomas may also benefit from this therapeutic strategy.
Although showing promising results, the present 
investigation presents limitations, being the most critical the 
low number of cases available to be tested. Further studies, with 
more robust series, are warranted to increase statistical power 
and allow additional findings, including verification of MCT4 
overexpression in malignant samples as well as association of 
the metabolic profile with clinicopathological data. Like in adult 
adrenocortical tumors, where GLUT1 was described as a stage-
independent predictor of clinical outcome [40], the proteins 
herein analyzed may show clinicopathological significance.
In the present study, GLUT1 expression was 
differentially expressed in pediatric ACTs, with a higher 
expression in clinically malignant tumors than clinically benign 
tumors, and was associated with shorter overall and disease-
free survival, suggesting a metabolic remodeling towards 
malignancy in these tumors.
MATERIAL AND METHODS
Human childhood adrenocortical tumor samples
The tumor series included 50 formalin-fixed 
paraffin-embedded ACTs (41 clinically benign and 9 
clinically malignant lesions), retrieved from the files of the 
Table 3: Detailed aspects for each antibody used in immunohistochemistry
Protein Antigen retrieval Antibody (product # and company) Antibody dilution and 
incubation time
MCT1 Citrate buffer (0.01 M, pH=6), 98ºC, 20’ AB3538P Merck-Millipore 1:200, overnight
MCT2 Citrate buffer (0.01 M, pH=6), 98ºC, 20 sc-50322 Santa Cruz Biotechnology 1:200, 2 hours
MCT4 Citrate buffer (0.01 M, pH=6), 98ºC, 20’ sc-50329 Santa Cruz Biotechnology 1:500, 2 hours
CD147 EDTA (1 mM, pH=8), 98ºC, 20’ sc-71038 Santa Cruz Biotechnology 1:400, overnight
CD44 Citrate buffer (0.01 M, pH=6), 98ºC, 20 MCA2726 AbD Serotec 1:2000, 2 hours
GLUT1 Citrate buffer (0.01 M, pH=6), 98ºC, 20’ ab15309-500 AbCam 1:500, 2 hours
CAIX Citrate buffer (0.01 M, pH=6), 98ºC, 20’ ab15086 AbCam 1:2000, 2 hours
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Pathology Department of the Clinical Hospital, School of 
Medicine, University of São Paulo, Brazil. Samples were 
organized into tissue microarrays (TMA) and each case 
was represented by three cores (1.0 mm diameter). Control 
samples (kidney) were included for TMA orientation. 
Cases were classified as clinically malignant if metastatic 
disease was detected. Clinicopathological data for the 
ACTs included age at diagnosis (non-normal distribution, 
median 2.2 years, range: 0.5 to 13 years), gender, TP53 
status, tumor size (non-normal distribution, median 
5.0 cm, range: 1.5 to 21.0 cm) and weight (non-normal 
distribution, median 40.0 mg, range: 4.0 to 650.0 mg), 
Weiss score and its individual histological parameters [8], 
staging (according to ENSAT system [56]), metastasis, 
progression-free survival and overall survival. Detailed 
information of the clinicopathological data for the 
childhood ACTs is presented in Table 2. The study was 
approved by the Local Ethic Committee (number 11090).
Immunohistochemistry
MCT1 immunohistochemistry was performed 
according to the avidin-biotin-peroxidase complex method 
(R.T.U. VECTASTAIN Elite ABC Kit (Universal), Vector 
Laboratories, Burlingame, CA), as previously described [57]. 
Immunohistochemistry for MCT2, MCT4, GLUT1, CD44 
and CAIX was performed according to the streptavidin-
biotin-peroxidase complex method (UltraVision Detection 
System Anti-polyvalent, HRP, Lab Vision Corporation, 
Fremont, CA), as previously described [58-60]. CD147 
immunostaining was performed using a polymer system 
(UltraVision ONE Detection System: HRP Polymer Lab 
Vision Corporation, Fremont, CA) as previously described 
[61]. Negative controls were performed by the use of 
appropriate serum controls for the primary antibodies (N1698 
and N1699, Dako, Carpinteria, CA). Colon carcinoma tissue 
was used as positive control for MCT1, MCT4, CD147 
and CD44, head and neck squamous cell carcinoma was 
used for GLUT1, and normal stomach was used for CAIX. 
Tissue sections were counterstained with hematoxylin and 
permanently mounted. Detailed aspects for each antibody 
used are depicted in Table 3.
Immunohistochemical evaluation
Sections were scored semi-quantitatively for extension 
of expression in cancer cells as follows: 0: no immunoreactive 
cells; 1: <5% of immunoreactive cells; 2: 5-50% of 
immunoreactive cells; and 3: >50% of immunoreactive cells. 
Also, intensity of staining was scored semi-qualitatively as 
follows: 0: negative; 1: weak; 2: intermediate; and 3: strong. 
The final score was defined as the sum of both parameters 
(extension and intensity), and grouped as negative (score 
0 and 2) and positive (score 3-6), as previously described 
[57]. Protein expression in the different cellular localizations 
(cytoplasm and plasma membrane) was evaluated separately.
Statistical analysis
Data were stored and analyzed using the IBM SPSS 
Statistics software (version 23, IBM Company, Armonk, 
NY). All comparisons were examined for statistical 
significance using Pearson’s chi-square (χ2) test or Fisher’s 
exact test (depending on group size). Overall survival 
was defined as the time from the date of complete tumor 
resection to death related to adrenocortical cancer or last 
follow-up. Disease-free survival was defined as the time 
from the date of complete tumor resection to the first 
radiological evidence of disease relapse or death. Overall 
and disease-free survival curves were estimated by the 
method of Kaplan-Meier and data compared using the log-
rank test. Due to the low number of malignant lesions (9/50, 
18%), no statistical analysis associating the expression of 
the metabolism-related proteins with the clinicopathological 
variables was performed. The threshold for significant p 
values was established as p<0.05.
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